← Back to Search

Experimental for Inguinal Hernia

Phase 2 & 3

Waitlist Available

Led By Celia M Divino, MD

Research Sponsored by Icahn School of Medicine at Mount Sinai

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up on post-op days 1-4

Summary

This trial tests if TAP blocks reduce pain and opioid use after inguinal hernia repair. It will also look for complications.

Eligible Conditions

Inguinal Hernia

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ on post-op days 1-4

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~on post-op days 1-4

This trial's timeline: 3 weeks for screening, Varies for treatment, and on post-op days 1-4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Pain Score

Secondary study objectives

Number of Complications

Number of non-opioid pain medication

Number of opioid pills

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: ExperimentalExperimental Treatment2 Interventions

0.25% bupivacaine: For patients weighing \<100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh\>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received.

Group II: PlaceboPlacebo Group2 Interventions

Normal Saline: For patients weighing \<100 kg, a total of 50 ml ((25 ml on each side of the abdominal wall) will be received. If patients weigh\>100 kg, a total of 60 ml (30ml on each side of the abdominal wall) will be received.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

0.25% Bupivacaine

2011

Completed Phase 4

~520

TAP block

2010

Completed Phase 4

~1950